Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer

Lung Cancer

Volumn 79, Issue 1, 2013, Pages 33-39

  Yang, Jin Ji ^a   Chen, Hua Jun ^a   Yan, Hong Hong ^a   Zhang, Xu Chao ^a   Zhou, Qing ^a   Su, Jian ^a   Wang, Zhen ^a   Xu, Chong Rui ^a   Huang, Yi Sheng ^a   Wang, Bin Chao ^a   Yang, Xue Ning ^a   Zhong, Wen Zhao ^a   Nie, Qiang ^a   Liao, Ri Qiang ^a   Jiang, Ben Yuan ^a   Dong, Song ^a   Wu, Yi Long ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Epidermal growth factor receptor; Failure; Mode; Non small cell lung cancer; Tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; SCATTER FACTOR RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; TREATMENT FAILURE; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT FAILURE; TUMOR BURDEN;

EID: 84871087595     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.09.016     Document Type: Article

References (44)

1. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
2. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
3. Han J.Y., Park K., Kim S.W., Lee D.H., Kim H.Y., Kim H.T., et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012, 30:1122-1128.
4. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
5. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
6. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.
7. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol 2012, 13:239-246.
8. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., et al. MET amplification occurs with or without T790M mutation in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007, 104:20932-20937.
9. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
10. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinoma to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
11. Nguyen K.S., Kobayashi S., Costa D.B. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009, 10:281-289.
12. Jackman D., Pao W., Riely G.J., Engelman J.A., Kris M.G., Jänne P.A., et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010, 28:357-360.
13. Chaft J.E., Oxnard G.R., Sima C.S., Kris M.G., Miller V.A., Riely G.J. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 2011, 17:6298-6303.
14. Lee Y.J., Choi H.J., Kim S.K., Chang J., Moon J.W., Park I.K., et al. Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with non-small-cell lung cancer. Cancer 2010, 116:1336-1343.
15. Ettinger D.S., Akerley W., Bepler G., Blum M.G., Chang A., Cheney R.T., et al. Non-small cell lung cancer. J Natl Compr Cancer Netw 2010, 8:740-801.
16. Kuo C.H., Lin S.M., Lee K.Y., Chung F.T., Hsieh M.H., Fang Y.F., et al. Subsequent chemotherapy improves survival outcome in advanced non-small-cell lung cancer with acquired tyrosine kinase inhibitor resistance. Clin Lung Cancer 2010, 11:51-56.
17. Riely G.J., Kris M.G., Zhao B., Akhurst T., Milton D.T., Moore E., et al. Prospective assessment of discontinuation and re-initiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007, 13:5150-5155.
18. Yokouchi H., Yamazaki K., Kinoshita I., Konishi J., Asahina H., Sukoh N., et al. Clinical benefit of re-administration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer 2007, 7:51.
19. Heigener D.F., Wu Y.L., van Zandwijk N., Mali P., Horwood K., Reck M. Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study. Lung Cancer 2011, 74:274-279.
20. Beasley M.B., Brambilla E., Travis W.D. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 2005, 40:90-97.
21. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
22. Detterbeck F.C., Boffa D.J., Tanoue L.T. The new lung cancer staging system. Chest 2009, 136:260-271.
23. Bergman B., Aaronson N.K., Ahmedzai S., Kaasa S., Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 1994, 30A:635-642.
24. van Puijenbroek R., Bosquée L., Meert A.P., Schallier D., Goeminne J.C., Tits G., et al. Gefitinib monotherapy in advanced non-small cell lung cancer: a large Western community implementation study. Eur Respir J 2007, 29:128-133.
25. Zhou Q., Zhang X.C., Chen Z.H., Yin X.L., Yang J.J., Xu C.R., et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol 2011, 29:3316-3321.
26. Beau-Faller M., Ruppert A.M., Voegeli A.C., Neuville A., Meyer N., Guerin E., et al. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort. J Thorac Oncol 2008, 3:331-339.
27. Chen H.J., Mok T.S., Chen Z.H., Guo A.L., Zhang X.C., Su J., et al. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. Pathol Oncol Res 2009, 15:651-658.
28. Oxnard G.R., Arcila M.E., Sima C.S., Riely G.J., Chmielecki J., Kris M.G., et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011, 17:1616-1622.
29. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361:958-967.
30. Hasegawa M., Sone S., Takashima S., Li F., Yang Z.G., Maruyama Y., et al. Growth rate of small lung cancers detected on mass CT screening. Br J Radiol 2000, 73:1252-1259.
31. Winer-Muram H.T., Jennings S.G., Tarver R.D., Aisen A.M., Tann M., Conces D.J., et al. Volumetric growth rate of stage I lung cancer prior to treatment: serial CT scanning. Radiology 2002, 223:798-805.
32. Kaira K., Naito T., Takahashi T., Ayabe E., Shimoyama R., Kaira R., et al. Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer. Lung Cancer 2010, 68:99-104.
33. An T., Huang Z., Wang Y., Wang Z., Bai H., Wang J. Retreatment with epidermal growth factor receptor inhibitor after initial failure in advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2011, 14:261-265.
34. Gow C.H., Chien C.R., Chang Y.L., Chiu Y.H., Kuo S.H., Shih J.Y., et al. Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. Clin Cancer Res 2008, 14:162-168.
35. Shukuya T., Takahashi T., Naito T., Kaira R., Ono A., Nakamura Y., et al. Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. Lung Cancer 2011, 74:457-461.
36. Hirano Y., Oda M., Tsunezuka Y., Ishikawa N., Watanabe G. Long-term survival cases of lung cancer presented as solitary bone metastasis. Ann Thorac Cardiovasc Surg 2005, 11:401-404.
37. Mercier O., Fadel E., de Perrot M., Mussot S., Stella F., Chapelier A., et al. Surgical treatment of solitary adrenal metastasis from non-small cell lung cancer. J Thorac Cardiovasc Surg 2005, 130:136-140.
38. Chmielecki J., Foo J., Somwar R., Regales L., Vivanco I., Shen R.L., et al. EGFR T790M mutation decrease growth potential of lung tumor cells with drug-sensitive EGFR mutant alleles in the absence of drug selection. AACR 100th annual meeting 2009, [Abstract 4217].
39. Engelman J.A., Mukohara T., Zejnullahu K., Lifshits E., Borrás A.M., Gale C.M., et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 2006, 116:2695-2706.
40. Kirsch D.G., Ledezma C.J., Mathews C.S., Bhan A.K., Ancukiewicz M., Hochberg F.H., et al. Survival after brain metastases from breast cancer in the trastuzumab era. J Clin Oncol 2005, 23:2114-2116.
41. Metro G., Sperduti I., Russillo M., Milella M., Cognetti F., Fabi A. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer. Oncologist 2007, 12:1467-1469.
42. Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wu Y.L., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
43. Park K., Tsai C.M., Ahn M.J., Yu C.J., Kim S.W., Sriuranpong V., et al. ASPIRATION: phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2012, 30(Suppl. 15). [Abstr TPS7614].
44. Chen Z.Y., Zhong W.Z., Zhang X.C., Su J., Yang X.N., Chen Z.H., et al. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist 2012, 17:978-985.